Proactive Investors - Run By Investors For Investors

OptiBiotix Health signs Russia and Kazakhstan distribution deal

The company is teaming up with SilvExpo, a local pharmaceutical and nutraceutical business
st basil's moscow
Dawning opportunity: The Russian probiotics market on its own is estimated by the firm to be worth €340mln

OptiBiotix Health plc (LON:OPTI) has inked a distribution agreement that will see its cholesterol and blood pressure product sold in Russia and Kazakhstan.

In the latest of a series of similar commercial deals, the company is teaming up with SilvExpo, a local pharmaceutical and nutraceutical business.

WATCH: OptiBiotix’s SlimBiome gathers steam as subsidiary eyes potential IPO

OptiBiotix’s probiotic CholBiomeX3, containing the LPLDL bacteria strain, will be stocked in pharmacies in the two countries.

The Russian probiotics market on its own is estimated by the firm to be worth €340mln, and is growing at 10% annually.

"We are pleased to announce this agreement which extends the sales channel of our CholBiome products into Russia and Kazakhstan where cardiovascular disease are the leading cause of morbidity and mortality,” said commercial director Per Rehné.

“We chose SilvExpo for its knowledge and speed to market and they have shown the ability to grow product sales in challenging markets.

“This agreement is a strategic step to build the distribution sales channel for CholBiome products in Eastern Europe and we anticipate that the agreement could produce revenues quickly."

On Monday, OptiBiotix, which is developing probiotic treatments for weight loss and diabetes as well as cholesterol lowering products, signed its ninth distribution customer for the SlimBiome range.

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use